BioCentury | Nov 17, 2014
Clinical News

Flubok regulatory update

...hemagglutinin antigens purified from cultured insect cells. Under an amended 2006 deal, Protein Sciences granted UMN Pharma...
...Hong Kong and Singapore (see BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights from UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Jun 9, 2014
Clinical News

Flubok regulatory update

...MHLW) for ASP7374 to prevent influenza infection. The submission triggered an undisclosed milestone payment to UMN Pharma...
...Protein Sciences will receive a portion of the milestone under an amended 2006 deal granting UMN Pharma...
...BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights in Japan under its deal with UMN Pharma...
BioCentury | Feb 24, 2014
Company News

UMN Pharma, Daiichi Sankyo deal

...and royalties, but declined to disclose financial terms. UMN could not be reached for details. UMN Pharma Inc....
BioCentury | Feb 10, 2014
Clinical News

Flublok: Phase III data

...seasonal influenza infection in adults ages 18-49 years (see BioCentury, Jan. 21, 2013). Astellas and UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Feb 10, 2014
Clinical News

Flublok: Phase III data

...seasonal influenza infection in adults ages 18-49 years (see BioCentury, Jan. 21, 2013). Astellas and UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Nov 4, 2013
Clinical News

ASP7374: Phase III ongoing

...Astellas and UMN Pharma said all subjects were vaccinated in an open-label, Japanese Phase III trial evaluating...
...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...and exclusive commercialization rights for the product in Korea. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Nov 4, 2013
Clinical News

ASP7374: Phase III ongoing

...Astellas and UMN Pharma said all subjects were vaccinated in a double-blind, Japanese Phase III trial comparing...
...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...and exclusive commercialization rights for the product in Korea. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Jul 1, 2013
Clinical News

Flublok regulatory update

...seasonal influenza vaccine made with recombinant hemagglutinin antigens purified from cultured insect cells. Astellas and UMN Pharma...
...commercialization rights for the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Mar 18, 2013
Clinical News

Flublok: Phase III data

...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...commercialization rights for the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Mar 11, 2013
Company News

API Co. Ltd., UMN Pharma, Yakult deal

...Yakult will be responsible for development and commercialization. API Co. Ltd. , Gifu City, Japan UMN Pharma Inc....
Items per page:
1 - 10 of 27
BioCentury | Nov 17, 2014
Clinical News

Flubok regulatory update

...hemagglutinin antigens purified from cultured insect cells. Under an amended 2006 deal, Protein Sciences granted UMN Pharma...
...Hong Kong and Singapore (see BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights from UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Jun 9, 2014
Clinical News

Flubok regulatory update

...MHLW) for ASP7374 to prevent influenza infection. The submission triggered an undisclosed milestone payment to UMN Pharma...
...Protein Sciences will receive a portion of the milestone under an amended 2006 deal granting UMN Pharma...
...BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights in Japan under its deal with UMN Pharma...
BioCentury | Feb 24, 2014
Company News

UMN Pharma, Daiichi Sankyo deal

...and royalties, but declined to disclose financial terms. UMN could not be reached for details. UMN Pharma Inc....
BioCentury | Feb 10, 2014
Clinical News

Flublok: Phase III data

...seasonal influenza infection in adults ages 18-49 years (see BioCentury, Jan. 21, 2013). Astellas and UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Feb 10, 2014
Clinical News

Flublok: Phase III data

...seasonal influenza infection in adults ages 18-49 years (see BioCentury, Jan. 21, 2013). Astellas and UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Nov 4, 2013
Clinical News

ASP7374: Phase III ongoing

...Astellas and UMN Pharma said all subjects were vaccinated in an open-label, Japanese Phase III trial evaluating...
...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...and exclusive commercialization rights for the product in Korea. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Nov 4, 2013
Clinical News

ASP7374: Phase III ongoing

...Astellas and UMN Pharma said all subjects were vaccinated in a double-blind, Japanese Phase III trial comparing...
...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...and exclusive commercialization rights for the product in Korea. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Jul 1, 2013
Clinical News

Flublok regulatory update

...seasonal influenza vaccine made with recombinant hemagglutinin antigens purified from cultured insect cells. Astellas and UMN Pharma...
...commercialization rights for the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Mar 18, 2013
Clinical News

Flublok: Phase III data

...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...commercialization rights for the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....
BioCentury | Mar 11, 2013
Company News

API Co. Ltd., UMN Pharma, Yakult deal

...Yakult will be responsible for development and commercialization. API Co. Ltd. , Gifu City, Japan UMN Pharma Inc....
Items per page:
1 - 10 of 27